此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

评估鞘内注射奥那西诺基因阿贝帕伏韦-brve(OAV101B)(ITVISMA®)治疗脊髓性肌萎缩症参与者的真实世界安全性与有效性:一项美国实用多中心研究(STREAM)

2026年10月28日 更新者:Novartis Pharmaceuticals

Onasemnogene Abeparvovec:评估接受鞘内注射Onasemnogene Abeparvovec-brve(ITVISMA®)治疗的脊髓性肌萎缩症参与者的真实世界安全性与有效性:一项美国实用多中心研究(STREAM)

The primary purpose is to address critical evidence in the treatment landscape for Spinal Muscular Atrophy (SMA), specifically focusing on the intrathecal formulation of onasemnogene abeparvovec-brve (ITVISMA®). U.S. Pragmatic Multicenter Study (STREAM).

研究概览

详细说明

STREAM is a prospective, multicentre cohort study that will follow U.S. participants with genetically confirmed SMA who receive a single, intrathecal dose of onasemnogene abeparvovec-brve. All eligible participants are enrolled prior to therapeutic injection. No randomisation, blinding, or placebo control is employed; instead, each participant acts as his or her own baseline comparator. This study will use an exploratory external cohort of patients matched by age, clinical characteristics, treatment history and availability of at least 1 year of pre-treatment medical history. This patient cohort will be based on a database of retrospectively collected electronic medical records data and will be used descriptively to contextualize study outcomes. Bias is minimised through pre-specified endpoints, uniform rater training on motor-function scales, and a detailed statistical analysis plan that stipulates handling of missing data and intercurrent events in advance.

研究类型

介入性

注册 (估计的)

36

阶段

  • 第四阶段

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

研究联系人备份

  • 姓名:Novartis Pharmaceuticals

学习地点

    • Arkansas
      • Little Rock、Arkansas、美国、208833
        • 招聘中
        • Arkansas Children's Hospital
        • 首席研究员:
          • Aravindhan Veerapandiyan
        • 接触:
          • Buffy Gofforth
          • 电话号码:(501) 364-1591
    • California
      • Stanford、California、美国、94305-5235
    • Massachusetts
      • Boston、Massachusetts、美国、02215
    • New York
      • New York、New York、美国、10032
        • 招聘中
        • Columbia University Medical Center
        • 首席研究员:
          • Claudia Chiriboga
        • 接触:
    • Ohio
      • Columbus、Ohio、美国、43210
        • 招聘中
        • Ohio State University Medical Center
        • 首席研究员:
          • Bakri Elsheikh
        • 接触:
    • Pennsylvania
      • Philadelphia、Pennsylvania、美国、209277
        • 招聘中
        • University of Pennsylvania
        • 首席研究员:
          • Lauren Elman
        • 接触:

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

2年 至 100年 (孩子、成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Key Inclusion Criteria:

A participant will be enrolled in STREAM only if all the following conditions are met:

  • The participant has a genetically confirmed diagnosis of SMA (biallelic SMN1 deletion or mutation).

  • He or she is ≥ 2 years of age on the day of the intrathecal injection.

  • The treating Investigator intends to administer within the current episode of care, a single dose of ITVISMA® (1.2 × 10¹⁴ vg) in routine U.S. practice after written informed consent obtained.

  • One of the following functional categories applies at screening:

    1. independently ambulatory child/adolescent 2 - <18 years; or
    2. independently ambulatory adult (≥ 18 years).
    3. non-ambulatory (includes walkers with assistance) adult > 18 years with entry level RULM at baseline
  • At least 1 year of pre-treatment medical history, including motor-function documentation, can be retrieved from the site electronic record.

Key Exclusion Criteria:

A participant will be excluded if any of the following conditions apply:

  • Contraindication for lumbar puncture as determined by the investigator (e.g., spinal anatomy that precludes safe lumbar puncture)
  • An uncontrolled acute illness, active infection, febrile illness or acute medical condition, within 30 days prior to dosing
  • Inability to tolerate corticosteroids administered by mouth or gastrostomy tube
  • Current participation in another interventional clinical trial that would interfere with the objectives or endpoints of STREAM. Note: participation in observational cohort studies or non-interventional studies in which the participant does not receive treatment or undergo procedures which may compromise this study data integrity may be allowed following Sponsor approval
  • Planned relocation or any circumstance that is likely to prevent completion of the minimum 12-month follow-up.

Other protocol inclusion, exclusion criteria may apply.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:不适用
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Onasemnogene Abeparvovec-brve

Participants with spinal muscular atrophy, including:

  • independently ambulatory children/adolescents (≥ 2 years to < 18 years);
  • independently ambulatory adults (≥ 18 years);
  • Non-ambulatory adults (≥ 18 years)

administered once via lumbar puncture with systemic corticosteroid prophylaxis per label.

其他名称:
  • (依维思玛®)

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Change from baseline in HFMSE for independently ambulatory participants
大体时间:Baseline, 6, 12, 18 and 24 months

The HFMSE is a validated SMA specific assessment devised for use in children with SMA to give objective information on motor ability and clinical progression.

The HFMSE contains 33 items rated from 0 (unable to perform) to 2 (performs without modification/adaptation/compensation). Total scores range from 0-66. Higher scores indicate higher levels of motor ability.

Baseline, 6, 12, 18 and 24 months
Change from baseline in RULM for non-ambulatory (including walkers with assistance) participants
大体时间:Baseline, 6, 12, 18 and 24 months

The RULM is a validated SMA specific assessment of motor performance in the upper limbs from childhood through adulthood in independent ambulatory and non-ambulatory (including walkers with assistance) individuals with SMA. The scale consists of 19 scorable items: 18 items scored on 0 (unable) to 2 (full achievement) scale, and one item that is scored from 0 (unable) to 1 (able). Total scores range from 0-37 points. Higher scores reflect higher level of motor ability.

Baseline, 6, 12, 18 and 24 months

次要结果测量

结果测量
措施说明
大体时间
Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs)
大体时间:up to 5 years

Incidence of AEs and SAEs, including changes in laboratory tests and procedure-related events qualifying and reported as AEs.

up to 5 years
Modified SMA Functional Rating Scale (SMA-FRS) for independently ambulatory participants (≥ 18 years of age) and non-ambulatory particpants
大体时间:Baseline, 6, 12, 18 and 24 months and Years 3, 4, and 5

Modified Spinal Muscular Atrophy Functional Rating Scale (SMAFRS): Ten items address questions related to eating, upper extremity dressing, lower extremity dressing, grooming, bathing, toileting, turning in bed and adjusting bed clothes, transfers, walking, and climbing stairs. This outcome measure includes effectiveness assessment across predefined participant groups based on relevant clinical and demographic factors, as specified in the protocol.

Baseline, 6, 12, 18 and 24 months and Years 3, 4, and 5
Assessment of Caregiver Experience with Neuromuscular Disease (ACEND) for independently ambulatory participants (<18 years of age)
大体时间:Baseline, Months 6, 12, 18, 24, and Years 3, 4, and 5

The Assessment of Caregiver Experience with Neuromuscular Disease (ACEND): quantifies caregivers' perceptions of function and quality of life pertaining to time, finance and emotion. The ACEND was developed and validated to specifically assess caregiver impact experienced by raising children severely affected by neuromuscular diseases. While specifically developed for application to caregivers of patients undergoing orthopedic surgery, it has application to those with SMA. This outcome measure includes effectiveness assessment across predefined participant groups based on relevant clinical and demographic factors, as specified in the protocol.

Baseline, Months 6, 12, 18, 24, and Years 3, 4, and 5
Subgroup outcomes: Hammersmith Functional Motor Scale Expanded (HFMSE)
大体时间:Baseline, 6, 12, 18 and 24 months

Effectiveness assessment across predefined participant groups based on relevant clinical and demographic factors, as specified in the protocol. The HFMSE is a validated SMA specific assessment to give objective information on motor ability and clinical progression. Total scores range from 0-66. Higher scores indicate higher levels of motor ability.

Baseline, 6, 12, 18 and 24 months
Subgroup outcomes: Revised Upper Limb Module (RULM)
大体时间:Baseline, 6, 12, 18 and 24 months

Effectiveness assessment across predefined participant groups based on relevant clinical and demographic factors, as specified in the protocol. The RULM is a validated SMA specific assessment of motor performance in the upper limbs from childhood through adulthood in independent ambulatory and non-independent ambulatory individuals with SMA. Total scores range from 0-37 points. Higher scores reflect higher level of motor ability.

Baseline, 6, 12, 18 and 24 months
Frequency of hospitalizations emergency department visits, outpatient visits, respiratory interventions and nutritional support interventions
大体时间:Baseline, Months 6, 12, 18, 24, and Years 3, 4, and 5

Assessment of SMA-related healthcare-resource utilisation.

Baseline, Months 6, 12, 18, 24, and Years 3, 4, and 5
Duration of hospitalizations emergency department visits, outpatient visits, respiratory interventions and nutritional support interventions
大体时间:Baseline, Months 6, 12, 18, 24, and Years 3, 4, and 5

Assessment of SMA-related healthcare-resource utilisation.

Baseline, Months 6, 12, 18, 24, and Years 3, 4, and 5
Cobb angle
大体时间:Baseline, up to 24 months

Assessment of scoliosis progression as a disease-progression marker.

Baseline, up to 24 months
Daily hours of respiratory support (none, non-invasive ventilation, invasive ventilation)
大体时间:Baseline, up to 24 months

Assessment of respiratory function as a disease-progression marker.

Baseline, up to 24 months
Joint-range limitation measured by goniometer
大体时间:Baseline, up to 24 months

Assessment of evolution of joint contractures as a disease-progression marker.

Baseline, up to 24 months
Nutritional-support category (oral, gastrostomy feeds, total parenteral nutrition)
大体时间:Baseline, up to 24 months

Assessment of nutrition status as a disease-progression marker.

Baseline, up to 24 months
6-Minute Walk Test (6MWT) for ambulatory patients
大体时间:Baseline, Months 6, 12, 18, and 24

To assess disease-progression markers. 6MWT: distance in metres; greater distance indicates better ambulatory capacity.

Baseline, Months 6, 12, 18, and 24

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2026年8月27日

初级完成 (估计的)

2032年5月3日

研究完成 (估计的)

2032年6月30日

研究注册日期

首次提交

2026年2月26日

首先提交符合 QC 标准的

2026年2月26日

首次发布 (实际的)

2026年3月4日

研究记录更新

最后更新发布 (实际的)

2026年10月29日

上次提交的符合 QC 标准的更新

2026年10月28日

最后验证

2026年10月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

是的

IPD 计划说明

Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com.

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅